RALA and pancreatic neoplasm: Although the exact molecular mechanism was not delineated, CDK5 may regulate the activation of RalA and RalB by controlling the function of either RalGEFs or RalGAP, suggesting CDK5 as a possible target for pancreatic cancer [59] (Fig. 2B).